Print
Print
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | November 21, 2024
The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel.
Melissa BadamoAcute Myeloid Leukemia | November 19, 2024
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
Leah LawrencePrint | November 18, 2024
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
Melissa BadamoPrint | November 15, 2024
Since 1974, Dr. Steven Rosenberg has served as Chief of the Surgery Branch at the NCI.
Melissa BadamoPrint | November 22, 2024
Dr. Lunning discusses his origins in clinical research, the rise of cellular therapy, and more.
Melissa BadamoPrint | November 15, 2024
The IMS presented annual awards to three multiple myeloma clinicians and researchers during the 21st Annual Meeting.
Advertisement
Andrew MorenoPrint | November 5, 2024
A retrospective study highlighted differences in infection rates and healthcare utilization following CAR-T therapy.
Melissa BadamoMyeloma | November 4, 2024
Mezigdomide, tazemetostat, and dexamethasone demonstrated promising efficacy and safety in relapsed or refractory MM.
Andrew MorenoPrint | November 4, 2024
A phase II trial in patients with at least three prior treatments evaluated two target doses of the CAR T-cell therapy.
Andrew MorenoPrint | November 4, 2024
The agent is newly approved in polytherapy with bortezomib and dexamethasone for multiple myeloma in adults.
Melissa BadamoChronic Myeloid Leukemia | October 30, 2024
The approval is based on results of the ASC4FIRST trial, which compared asciminib versus investigator-selected TKIs.
Andrew MorenoPrint | November 4, 2024
The agent is a first-of-its-kind, orally available, selective inhibitor of the nuclear export protein exportin 1.
Melissa BadamoPrint | October 10, 2024
Dr. Luskin describes why she pursued hematology-oncology, how she overcomes career challenges, and more.
Melissa BadamoPrint | October 9, 2024
Dr. Scheinberg succeeds Guillermo Garcia-Manero, MD, as president of the Society of Hematologic Oncology.
Melissa BadamoPrint | October 9, 2024
Ching-Hon Pui, MD, and John Seymour, MBBS, FRACP, PhD, were recognized for their contributions to blood cancer research.
Melissa BadamoPrint | October 8, 2024
SOHO is teaming up with ABHH for a joint session at the 2024 HEMO meeting in São Paulo, Brazil October 23-26.
Leah LawrencePrint | October 8, 2024
While research on CHIP has gained momentum in recent years, treating the premalignant condition remains in debate.
Sagar Lonial, MD, FACPPrint | October 7, 2024
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, reflects on life as an oncologist in 2024.
Andrew MorenoPrint | October 2, 2024
The anti-CD19 autologous CAR-T-cell therapy was approved for use in adults with relapsed or refractory disease.
Melissa BadamoMyeloma | October 2, 2024
The new indication for daratumumab and hyaluronidase-fihj plus D-VRd is based on results from the phase II CEPHEUS study.
Advertisement
Advertisement
Editorial Board